<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760642</url>
  </required_header>
  <id_info>
    <org_study_id>CYP_metabolomics</org_study_id>
    <nct_id>NCT01760642</nct_id>
  </id_info>
  <brief_title>Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity</brief_title>
  <official_title>Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity in Female Subjects Using Metabolomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification and evaluation of endogenous markers for the assessment of CYP3A activity in&#xD;
      female subjects using metabolomics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility for participation of this study will be determined from demographic information,&#xD;
      medical history, physical examination, electrocardiogram(ECG) and clinical laboratory tests&#xD;
      within 3 weeks before study drug administration. Subjects suitable for this study will be&#xD;
      admitted to the Clinical Trials Center, Seoul National University Hospital on the day before&#xD;
      dosing, and they will be overnight-fasted from 9 p.m. of Day -1. Urine collection is&#xD;
      scheduled from 24 hours before midazolam administration to 24 hours after administration.&#xD;
      Subjects will be dosed midazolam by intravenous around at 9 a.m. of Day 1. Subjects will&#xD;
      perform scheduled procedures including clinical laboratory tests, electrocardiograms and&#xD;
      pharmacokinetic samplings. Subjects will be discharged on Day 2 and visit the Clinical Trials&#xD;
      Center for period 2, ketoconazole administration. After 3 days of ketoconazole&#xD;
      administration, midazolam will be dosed with ketoconazole on Day 4 of period 2. Subjects will&#xD;
      perform scheduled procedure and on period 3 rifampicin will be dosed for 9 days and on Day 10&#xD;
      of period 3 midazolam will be dosed with rifampicin. After subjects perform scheduled&#xD;
      procedure, the study will be terminated 6-8 days after the end of period 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomic profile</measure>
    <time_frame>-24--12h, -12-0h of every midazolam dosing</time_frame>
    <description>endogenous metabolite profiles such as steroid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>0h, 10m, 20m, 30m, 45m, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h of every midazolam dosing</time_frame>
    <description>Cmax, AUClast of midazolam</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.&#xD;
period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam 3 mg IV</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Midazolam (Bukwang Pharm.Co., Ltd.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>ketoconazole 400 mg PO</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Kaszole (Skynewpharm Inc.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin 600 mg PO</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Rifampin (Yuhan Corp.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: Between 20 to 50 years of age, inclusive&#xD;
&#xD;
          -  Weight: Between 45 to 95 kg, within 17 - 28 of Body Mass Index&#xD;
&#xD;
          -  Menstruation cycle between 21 to 35 without contraceptive&#xD;
&#xD;
          -  Subject who agree contraception during the study&#xD;
&#xD;
          -  Subject who are reliable and willing to make themselves available during the study&#xD;
             period, are willing to follow the study protocol, and give their written informed&#xD;
             consent voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitive reaction to medication (midazolam, ketoconazole, rifampicin)&#xD;
&#xD;
          -  History of significant clinical illness needs medical caution, including&#xD;
             cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory,&#xD;
             gastrointestinal, hepatic, or renal disease or other chronic disease history or&#xD;
             evidence of drug abuse&#xD;
&#xD;
          -  A subject whose lab test results are as follows; Liver function test (AST, ALT, GGT,&#xD;
             ALP, LDH, Total bilirubin) &gt; 1.25 X upper limit of reference range&#xD;
&#xD;
          -  A subject whose SBP is over 140 mmHg or below 90 mmHg and DBP is over 100 mmHg or&#xD;
             below 50 mmHg&#xD;
&#xD;
          -  Presence or history of drug abuse or positive result in urine drug screening test&#xD;
&#xD;
          -  Blood donation during 2 months or apheresis during 1 month before the study&#xD;
&#xD;
          -  Use any prescriptive medication, Korean traditional medication not considered&#xD;
             acceptable by the clinical investigator during the last 14 days period before first&#xD;
             dosing, or use any OTC medication not considered acceptable by the clinical&#xD;
             investigator during the last 7 days period before first dosing (if used medication is&#xD;
             considered acceptable by investigator, patients can be included)&#xD;
&#xD;
          -  Use of alcohol over 21 units/weeks&#xD;
&#xD;
          -  Smoker who smoke more than 10 cigarettes per day&#xD;
&#xD;
          -  Participation in clinical trials of any drug within 60 days prior to the participation&#xD;
             of the study&#xD;
&#xD;
          -  Use of grapefruit juice within 1 week before first dose&#xD;
&#xD;
          -  Use of caffeine drink within 3 days before first dose&#xD;
&#xD;
          -  Subject pregnant or breast-feeding&#xD;
&#xD;
          -  Judged to be inappropriate for the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Youn Cho, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National Universtiy Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Joo-Youn Cho</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>metabolite profiles</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>CYP3A</keyword>
  <keyword>metabolomics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

